|
|
|
|
NICE says pharma should help pay for leukemia drugs
Government regulators in Britain are asking Novartis and Bristol-Myers Squibb to help pay for their leukemia drugs.In a statement today, the National Institute for Health and Clinical Excellence (NICE) took issue with price points on BMS's Sprycel and ...
|
|
|
CORRECT: FDA: Low Response Rate Seen With Proposed Drug Omapro
('FDA Low Response Rate Seen With Proposed Drug Omapro >CXS.AU', published at 10:12 a.m.EST, mistated the name of a type of leukemia. A correct version follows.) Of DOW JONES NEWSWIRES WASHINGTON -(Dow Jones)- The Food and Drug Administration said...
|
|
|
CORRECT: FDA: Low Response Rate Seen With Proposed Drug Omapro
("FDA Low Response Rate Seen With Proposed Drug Omapro >CXS.AU", published at 10:12 a.m.EST, mistated the name of a type of leukemia. A correct version follows.) WASHINGTON -(Dow Jones)- The Food and Drug Administration said Monday that the response...
|
|
|
UPDATE: FDA: Low Response Rate Seen With Proposed Drug Omapro
(Updates with FDA panel meeting postponement) WASHINGTON -(Dow Jones)- The Food and Drug Administration said Monday that the response rate seen in a study of a proposed ChemGenex Pharmaceuticals Ltd.(CXSPY, CXS.AU) drug to treat certain type of patients with...
|
|
|
CORRECT: FDA: Low Response Rate Seen With Proposed Drug Omapro
("FDA Low Response Rate Seen With Proposed Drug Omapro >CXS.AU", published at 10:12 a.m.EST, mistated the name of a type of leukemia. A correct version follows.) WASHINGTON -(Dow Jones)- The Food and Drug Administration said Monday that the response...
|
|
|
UPDATE: FDA: Low Response Rate Seen With Proposed Drug Omapro
(Updates with FDA panel meeting postponement) WASHINGTON -(Dow Jones)- The Food and Drug Administration said Monday that the response rate seen in a study of a proposed ChemGenex Pharmaceuticals Ltd.(CXSPY, CXS.AU) drug to treat certain type of patients with...
|
|
|
CORRECT: FDA: Low Response Rate Seen With Proposed Drug Omapro
("FDA Low Response Rate Seen With Proposed Drug Omapro CXS.AU", published at 9:57 a.m.EST, mistated the name of a type of leukemia. A correct version follows.) By Jennifer Corbett Dooren Of DOW JONES NEWSWIRES WASHINGTON -(Dow Jones)- The Food and Drug...
|
|
|
CORRECT: FDA: Low Response Rate Seen With Proposed Drug Omapro
('FDA Low Response Rate Seen With Proposed Drug Omapro >CXS.AU', published at 10:12 a.m.EST, mistated the name of a type of leukemia. A correct version follows.) Of DOW JONES NEWSWIRES WASHINGTON -(Dow Jones)- The Food and Drug Administration said...
|
|
|
UK says Novartis, Bristol cancer drugs too costly
* Watchdog recommends against Afinitor, Tasigna and Sprycel * Limited data to back benefits of three pricey drugs - NICE LONDON, Feb 9 (Reuters) - Britain's cost-effectiveness watchdog recommended against two expensive cancer drugs from Novartis AG (NOVN...
|
|
|
NICE warns industry on cost-effectiveness
NICE has turned down three drugs on cost grounds and has urged the pharma industry to do more to help the NHS when it comes to money.Updated draft guidance for Bristol Myers-Squibbs Sprycel (dasatinib) and Novartis Tasigna (nilotinib) for chronic...
|
|
|
UK says Novartis, Bristol cancer drugs too costly
* Watchdog recommends against Afinitor, Tasigna and Sprycel * Limited data to back benefits of three pricey drugs - NICE LONDON, Feb 9 (Reuters) - Britain's cost-effectiveness watchdog recommended against two expensive cancer drugs from Novartis AG and...
|
|
|
UK Body Says Novartis, Bristol Cancer Drugs Too Expensive
LONDON -(Dow Jones)- The U.K.'shealth-cost regulator said Tuesday it was unable to recommend two expensive cancer drugs from Novartis AG (NVS) and one from U.S.-based Bristol-Myers Squibb Co.(BMY) for use within the state-run National Health Service in...
|
|
|
UK Body Says Novartis, Bristol Cancer Drugs Too Expensive (DJ)
UK Body Says Novartis, Bristol Cancer Drugs Too Expensive LONDON -(Dow Jones)- The U.K.'s health-cost regulator said Tuesday it was unable to recommend two expensive cancer drugs from Novartis AG (NVS) and one from U.S.-based Bristol-Myers Squibb Co.(BMY)...
|
|
|
UK Body Says Novartis, Bristol Cancer Drugs Too Expensive
LONDON -(Dow Jones)- The U.K.'s health-cost regulator said Tuesday it was unable to recommend two expensive cancer drugs from Novartis AG (NVS) and one from U.S.-based Bristol-Myers Squibb Co.(BMY) for use within the state-run National Health Service in...
|
|
|
How Much Should Cancer Drugs Cost?
Suppose a hypothetical drug cost $10 million, was likely to extend life by only a day or two and didnt improve quality of life.Should insurance pay for the drug? Probably not it would increase the cost for everyone paying premiums, without doing much to...
|
|
|
NICE to drugmakers: Share our costs
The U.K.'s National Institute of Clinical Excellence has issued a new round of cancer-drug refusals.The drugs simply cost too much, NICE says. And to high prices, the cost-effectiveness watchdog always responds the way Queen Victoria did to a boorish guest...
|
|
|
Watchdog says Novartis, Bristol cancer drugs too costly
LONDON (Reuters) - Britain's cost-effectiveness watchdog recommended against two expensive cancer drugs from Novartis AG and one from Bristol-Myers Squibb Co being used within the state-run health service.It also rebuffed the Switzerland-based company's ...
|
|
|
UPDATE: FDA: Low Response Rate Seen With Proposed Drug Omapro
(Updates with FDA panel meeting postponement) Of DOW JONES NEWSWIRES WASHINGTON -(Dow Jones)- The Food and Drug Administration said Monday that the response rate seen in a study of a proposed ChemGenex Pharmaceuticals Ltd.( CXSPY, CXS.AU) drug to treat...
|
|
|
Watchdog says Novartis, Bristol cancer drugs too costly
Britain's cost-effectiveness watchdog recommended against two expensive cancer drugs from Novartis AG and one from Bristol-Myers Squibb Co being used within the state-run health service.It also rebuffed the Switzerland-based company's Tasigna and...
|
|
|
Watchdog says Novartis, Bristol cancer drugs too costly
Britain's cost-effectiveness watchdog recommended against two expensive cancer drugs from Novartis AG and one from Bristol-Myers Squibb Co being used within the state-run health service.It also rebuffed the Switzerland-based company's Tasigna and...
|
|
|
UPDATE: FDA: Low Response Rate Seen With Proposed Drug Omapro
(Updates with FDA panel meeting postponement) By Jennifer Corbett Dooren Of DOW JONES NEWSWIRES WASHINGTON -(Dow Jones)- The Food and Drug Administration said Monday that the response rate seen in a study of a proposed ChemGenex Pharmaceuticals Ltd.(CXSPY,...
|
|
|
UPDATE: FDA: Low Response Rate Seen With Proposed Drug Omapro
(Updates with FDA panel meeting postponement) Of DOW JONES NEWSWIRES WASHINGTON -(Dow Jones)- The Food and Drug Administration said Monday that the response rate seen in a study of a proposed ChemGenex Pharmaceuticals Ltd.( CXSPY, CXS.AU) drug to treat...
|
|
|
Watchdog says Novartis, Bristol cancer drugs too costly
The National Institute for Health and Clinical Excellence (NICE) said on Tuesday it was unable to recommend Afinitor from Novartis as a second-line treatment for kidney cancer, adding there was limited data about how long it could extend life.It also...
|
|
|
UK says Novartis, Bristol cancer drugs too costly
LONDON (Reuters) - Britain's cost-effectiveness watchdog recommended against two expensive cancer drugs from Novartis AG and one from Bristol-Myers Squibb Co (Bristol-Myers Squibb) being used within the state-run health service.The National Institute for...
|
|
|
UK says Novartis, Bristol cancer drugs too costly
Britain's cost-effectiveness watchdog recommended against two expensive cancer drugs from Novartis AG and one from Bristol-Myers Squibb Co being used within the state-run health service.It also rebuffed the Switzerland-based company's Tasigna and...
|
